Core Viewpoint - The company has submitted a CE mark registration application for its GeminiOne transcatheter edge-to-edge repair (TEER) system aimed at treating mitral valve regurgitation, marking a significant step in its global strategy [1] Group 1: Product Development - GeminiOne is an internally developed innovative TEER device featuring a unique sliding groove mechanical structure that maintains a small implant size and delivery system while achieving a longer grasping arm length [1] - The device includes innovative features such as an independent leaflet capture function to reduce surgical complexity, an automatic locking mechanism to prevent repeated locking and unlocking during the procedure, and a multi-angle release design to accommodate a wider range of anatomical structures [1] - The design of GeminiOne has been patented globally and has passed multiple freedom-to-operate analyses [1] Group 2: Regulatory Progress - As of the announcement date, the registration application for GeminiOne has been accepted by the National Medical Products Administration of China and is currently under review [1] - Additionally, GeminiOne has received an investigational device exemption from the U.S. Food and Drug Administration to conduct early feasibility studies [1] - The company is actively advancing the registration process for this product in China and Europe, aiming to provide safe and effective treatment options for patients with mitral valve regurgitation as soon as possible [1]

Core Viewpoint - The company has submitted a CE mark registration application for its GeminiOne® transcatheter edge-to-edge repair (TEER) system for the treatment of mitral valve regurgitation, marking a significant step in its global strategy [1] Group 1: Product Development - GeminiOne® is an innovative TEER device developed in-house, featuring a unique sliding mechanical structure that maintains a small implant size and delivery system while achieving longer grasping arm lengths [1] - The device includes innovative features such as an independent leaflet capture function to reduce surgical complexity, an automatic locking mechanism to prevent repeated locking and unlocking during the procedure, and a multi-angle release design to accommodate a wider range of anatomical structures [1] - The design of the GeminiOne® system has been patented globally and has passed multiple freedom-to-operate analyses [1] Group 2: Regulatory Progress - As of the announcement date, the registration application for GeminiOne® has been accepted by the National Medical Products Administration of China and is currently under review [1] - The GeminiOne® device has received an investigational device exemption from the U.S. Food and Drug Administration to conduct early feasibility studies [1] - The company is actively advancing the registration process for the product in China and Europe, aiming to provide safe and effective treatment options for patients with mitral valve regurgitation as soon as possible [1]

沛嘉医疗-B(09996.HK)获首席执行官兼董事长张一增持不超过1500万港元公司股份 沛嘉医疗- B(09996.HK)：国家药监局受理GeminiOne®经导管缘对缘修复系统的注册申请 相关事件 格隆汇12月5日丨沛嘉医疗-B(09996.HK)公告，董事会获悉，张一透过其所控制的公司，自2025年12月1 日起开始于公开市场上购买公司股份(「持股增加」)。持股增加合共代价预期不超过1500万港元。 ...

Major Events - Yuan Da Zhu Gong (02163) plans to apply for bankruptcy reorganization at Changsha Intermediate People's Court [1] - Yi Li Holdings (00076) subsidiary intends to issue blockchain vouchers V76, redeemable for bulk commodities on the platform [1] - Peijia Medical-B (09996): National Medical Products Administration accepts registration application for GeminiOne® transcatheter edge-to-edge repair system [1] - Paggen Biopharmaceutical-B (02565) proposes to grant exclusive license for VISEPEGENATIDE (PB-119) in the Middle East and Africa [1] - Beijing Enterprises Environment Group (00154) bids for Hong Kong I·PARK 2 project [1] - Fangda Holdings (01521) plans to acquire Shanghai Guanhua Medical Technology Co., Ltd. for 270 million yuan to enhance global laboratory service capabilities [1] - Lianzhong (06899) focuses on female user value, driving new entertainment through content [1] - Global New Materials International (06616) increases stake in CQV to 50.75%, strengthening global business collaboration [1] - Qianxin Biotechnology-B (02509): Qianxin's industrialization base successfully passes EU QP audit [1] - China Energy Construction (03996) subsidiary signs three new energy general contracting agreements, totaling approximately 19.554 billion yuan [1] - Yongyi International (01218) plans to sell all issued shares of Zhuoyi to Gaoshan (00616) [1] - Bohai Bank (09668) plans to list high capital-occupying debt assets for sale, with an initial pricing of no less than 48.883 billion yuan [1] - Chuangsheng Holdings (02680) plans to receive a premium of about 6% for full acquisition offer, resuming trading on October 13 [1] - Kelun-Botai Biopharmaceutical (06990): Core product TROP2ADC, Lukan-Satuzi (SAC-TMT) approved by National Medical Products Administration for third indication, treating EGFR mutation non-small cell lung cancer after EGFR-TKI progression [1] Operating Performance - Zhaojin Mining (01818) reports net profit of approximately 2.117 billion yuan for the first three quarters, a year-on-year increase of 140.43% [2] - Sunny Optical Technology (02382): September mobile phone camera module shipments reach 48.524 million units, a month-on-month increase of 15.3% and a year-on-year increase of 32% [2] - Yuexiu Property (00123) reports cumulative contract sales of approximately 79.812 billion yuan for the first nine months, a year-on-year increase of about 2.8% [2] - Qiu Tai Technology (01478) reports September camera module sales of 46.654 million units, a month-on-month decrease of 7.6% but a year-on-year increase of 45.1% [2]

Core Viewpoint - The company has received confirmation from the National Medical Products Administration regarding the acceptance of its registration application for the GeminiOne® transcatheter edge-to-edge repair (TEER) system [1] Group 1: Product Innovation - GeminiOne® is an internally developed innovative TEER device featuring a unique sliding groove mechanical structure that maintains a smaller implant size and delivery system while achieving a longer grasping arm length [1] - The device includes innovative features such as an independent leaflet capture function that reduces surgical complexity, an automatic locking mechanism to prevent repeated locking and unlocking during the procedure, and a multi-angle release design that accommodates a wider range of anatomical structures [1]

Core Viewpoint - The company has received confirmation from the National Medical Products Administration of China regarding the acceptance of its registration application for the GeminiOne® Transcatheter Edge-to-Edge Repair (TEER) system [1] Group 1: Product Innovation - GeminiOne® is an internally developed innovative TEER device featuring a unique sliding groove mechanical structure that maintains a small implant size and delivery system while achieving a longer grasping arm length [1] - The device includes an independent leaflet capture function that reduces surgical complexity, an automatic locking mechanism to prevent repeated locking and unlocking during the procedure, and a multi-angle release design that accommodates a wider range of anatomical structures [1]